Maxzide and Salivary hypersecretion - a phase IV clinical study of FDA data

Summary:

Salivary hypersecretion is reported as a side effect among people who take Maxzide (hydrochlorothiazide; triamterene), especially for people who are female, 60+ old, also take Prozac, and have Asthma.

The phase IV clinical study analyzes which people have Salivary hypersecretion when taking Maxzide. It is created by eHealthMe based on reports of 8,853 people who have side effects when taking Maxzide from the FDA, and is updated regularly.

What is Maxzide?

Maxzide has active ingredients of hydrochlorothiazide; triamterene. It is often used in high blood pressure. eHealthMe is studying from 9,152 Maxzide users. Check the latest studies of Maxzide.

What is Salivary hypersecretion?

Salivary hypersecretion (excess saliva secretion) is found to be associated with 781 drugs and 1,338 conditions by eHealthMe. Check the latest studies of Salivary hypersecretion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

8,853 people reported to have side effects when taking Maxzide.
Among them, 11 people (0.12%) have Salivary hypersecretion.

Could Maxzide cause Salivary hypersecretion?

Among these 11 people:

What is the gender of people who have Salivary hypersecretion when taking Maxzide? *

female: 63.64 %
male: 36.36 %

What is the age of people who have Salivary hypersecretion when taking Maxzide? *

What are other drugs people take besides Maxzide? *

What are other side effects people have besides Salivary hypersecretion? *

Ventricular Fibrillation (abnormally irregular heart rhythm): 4 people, 36.36%
Collapse (sudden functional breakdown): 4 people, 36.36%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 18.18%
Oral Discomfort (pain or irritation in mouth): 2 people, 18.18%
Throat Irritation: 2 people, 18.18%
Taste - Impaired: 2 people, 18.18%
Sinus Tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node): 2 people, 18.18%
Heart Rate Increased: 1 person, 9.09%
Headache (pain in head): 1 person, 9.09%
Hair Loss: 1 person, 9.09%

What are the existing conditions these people have? *

Asthma: 3 people, 27.27%
Osteoporosis (bones weak and more likely to break): 1 person, 9.09%
Breast Cancer: 1 person, 9.09%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Maxzide and have Salivary hypersecretion?

- Check whether Salivary hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Maxzide:

Maxzide (9,152 reports)

Salivary hypersecretion treatments and more:

Salivary hypersecretion (13,837 reports)

How severe was Salivary hypersecretion and when was it recovered:

Salivary hypersecretion in Maxzide

Expand to all the drugs that have ingredients of hydrochlorothiazide; triamterene:

Salivary hypersecretion and drugs with ingredients of hydrochlorothiazide; triamterene (37 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Maxzide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Salivary hypersecretion:

Salivary hypersecretion (781 drugs)

Browse all the conditions that are associated with Salivary hypersecretion:

Salivary hypersecretion (1,338 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydrochlorothiazide; triamterene (the active ingredients of Maxzide) and Maxzide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.